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Abstract
Background: Salmonella enterica, serovar Typhi (S. Typhi), a causative agent of enteric fever (typhoid fever),
predominately affects populations in developing regions with poor access to clean food and water. In addition,
travelers to these regions are at risk of exposure.
Methods: We report the epidemiological characteristics of S. Typhi cases among active duty United States military
personnel from 1998 to 2011 using data obtained from the Defense Medical Surveillance System. Cases were
identified based on International Classification for Disease Ninth Edition - Clinical Modification codes.
Results: We identified a total of 205 cases S. Typhi for an incidence of 1.09 per 100,000 person-years. Cases were on
average 31.7 years old, predominately married (n = 129, 62.9 %), Caucasian (n = 142, 69.3 %), male (n = 176, 85.9 %),
and had a high school education (n = 101, 49.3 %). Of the identified cases, 122 had received a Typhoid vaccination
within 4 years of diagnosis.
Conclusion: This study provides an overview of enteric fever in the United States military. The incidence was
similar to the general U.S. population except for increased incidence from 1998 to 2000, perhaps attributable to
operational deployments in that period. Given that vaccination is an effective primary prevention measure against
typhoid fever, active monitoring of pre-deployment vaccine history is warranted.
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Background
Typhoid fever, caused by infection with the Salmonella
enterica, serovar Typhi (S. Typhi), is transmitted by in-
gestion of food or beverage contaminated with fecal
matter, and accounts for a considerable burden of dis-
ease in areas lacking clean water or satisfactory sanita-
tion [1, 2]. Over 21 million cases of typhoid fever and
200,00 attributable deaths occur globally each year with
high incidence estimates of greater than 100 cases per
100,000 person-years (100 K p-y) in south-central and
south-east Asia [3]. However, in communities that have
access to clean water and adequate sanitation such as
Europe, Australia and North America, typhoid fever is
relatively uncommon with low incidence estimates of
less than ten cases per 100 K p-y. These cases are usu-
ally related to travel to endemic areas to include trav-
elers visiting friends and relatives [4, 5].
Essential measures to prevent infection with S. Typhi are
safe water access, safe food handling practices, sanitation
measures, and public education. Vaccination is also an
important precaution to prevent enteric infection, es-
pecially in individuals travelling to endemic areas, dur-
ing outbreak, or routinely in school-aged children
wherever the control of disease is a priority [2, 6].
Currently, two typhoid vaccines are commercially
available in the U.S., the Ty21a (oral) vaccine and the
Vi polysaccharide (parenteral) vaccine [7]. In the past,
two additional parenteral typhoid vaccines were also com-
monly administered, an acetone-inactivated (AKD) paren-
teral vaccine (only available to the U.S. armed forces) and
a heat-phenol (H-P) inactivated vaccine. However, the use
of AKD and H-P inactivated vaccines has become obsolete
secondary to poor side-effect profiles and because these
vaccines are not considered to be more effective than
other available typhoid vaccines (Table 1) [6, 8–10].
We reviewed data of cases of typhoid fever from the
Defense Medical Surveillance System, identified based
on an International Classification for Disease Ninth Edi-
tion - Clinical Modification from 1998–2011. Our pri-
mary goal was to describe the epidemiology of S. Typhi
cases in the U.S. military.* Correspondence: chad.k.porter2.civ@mail.mil
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Methods
S. Typhi cases were identified from all active duty U.S.
military personnel from 1998 to 2011. Cases were defined
based on a medical encounter in which the International
Classification of Disease, Ninth Revision-Clinical Modifi-
cation (ICD-9-CM) code for Typhoid fever (002.0) was
assigned. Descriptive analyses included estimates of S.
Typhi vaccination within 4 years of infection and the
frequency of documented cases among U.S. military popu-
lations over time and across multiple demographic charac-
teristics. All statistical analyses were performed using SAS
v. 9.2 for Windows (SAS Institute, Cary, NC).
Medical encounter data were obtained from the
Defense Medical Surveillance System (DMSS) which
includes Standard Ambulatory Data Record (SADR),
Comprehensive Ambulatory Patient Encounter Record
(CAPER) and Standard Inpatient Data Record (SIDR)
claims data for care obtained within the Military
Health Services and the Tri-Service Reportable Events
System data as well as demographic information from
personnel data and immunization data from the Defense
Enrollment Eligibility Reporting System (DEERS). Data
were supplied by the Armed Forces Health Surveillance
Center (AFHSC), which oversees the DMSS [11]. Military
population demographic data were provided by the
Defense Medical Data CenterPrior to providing the data
to investigators, personnel at AFHSC linked all available
information on selected subjects using the defined ICD-9
codes and requested fields into SAS data files and re-
moved all individually identifiable information.
The study protocol was approved by the Naval Medical
Research Center Institutional Review Board in compliance
with all applicable Federal regulations governing the pro-
tection of human subjects.
Results
Between 1998 and 2011, 205 cases of typhoid fever were
identified among U.S. military service members (Table 2).
The mean age of identified cases was 31.7 (standard devi-
ation: 7.6) years and cases were predominately (n = 129,
62.9 %), Caucasian (n = 142, 69.3 %), male (n = 176,
85.9 %), and had a high school education (n = 101,
49.3 %). Furthermore, subjects were more commonly
Navy (n = 78, 38.1 %) or Air Force (n = 73, 35.6 %) service
members (Fig. 1a–d). Prior to 2000, S. Typhi incidence
among males was non-significantly higher than that of
their female counterparts with 2.41 cases per 100 K p-y as
opposed to 1.55 cases per 100 K p-y in females (p = 0.30).
Notably, there was a marked increase in female incidence
in 2000 to 5.6 cases per 100 K p-y. Subsequent to 2000,
there was a gradual decline in typhoid fever incidence of
both genders to less than one case per 100 K p-y by 2002.
In evaluating incidence among the different services,
the greatest incidence of S. Typhi infection was ob-
served during 1998 in the Air Force with approxi-
mately 11.9 cases per 100 K p-y. Second to that, there
were approximately nine cases per 100 K p-y observed
in the Navy during the year 2000. Following the peak
in 2000, annual incidence among all branches was ob-
served to be less than two cases per 100 K p-y. When
stratifying incidence by race, Asians had the highest
incidence in 2000 with ten cases per 100 K p-y.
American Indians had the next highest incidence in
2004, with 5.2 cases per 100 K p-y. Stratifying inci-
dence by age showed the highest incidence among in-
dividuals older than 35 in the year 2000. Incidence in
the year 2000 among individuals between 35 and 39
was 6.8 cases per 100 K p-y and incidence among indi-
viduals aged 40 or greater was 5.2 cases per 100 K p-y.
Of the identified S. Typhi cases, 26 % (n = 53) of sub-
jects received a typhoid vaccination of any type within
2 years prior to diagnosis (Table 3). Approximately 63 %
(n = 130) of subjects had no documentation of S. Typhi
vaccination in the 3 years prior to S. Typhi infection and
nearly 82 % (n = 168) had no documentation of S. Typhi
vaccination in the 1 year prior to S. Typhi infection. The
most commonly administered vaccine was “any paren-
teral vaccine other than AKD”, which was administered
to 35.3 % (n = 72) of subjects. The least commonly ad-
ministered vaccine was the live oral vaccine, adminis-
tered to 8.8 % (n = 18) of S. Typhi cases. Importantly,
the parenteral acetone-inactivated (AKD) vaccine (U.S.
armed forces only) and the parenteral H-P vaccine have
not been in widespread use since 2005 or earlier [8].
Discussion
We conducted a 13-year retrospective case series study
to describe the epidemiological characteristics of S.
Typhi infection among active duty military personnel
from 1998 to 2011. All subjects were identified as having
Table 1 Summary of typhoid fever vaccines [6, 13–16]
Typhoid vaccine Route 3-year efficacy Booster Adverse reactions
Local Systemic
Vi Polysaccharide Parenteral 30–70 % 2 years 10–40 % 2 %
Live Ty21a Oral 34–58 % 5 years NA <1 %
Parenteral heat-phenol inactivated Parenteral 51–77 % 3 years 10–50 % 10–20 %
Acetone-inactivated Parenteral 75–94 % Not applicable 10–50 % 10–20 %
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S. Typhi by ICD9-CM code. We identified a peak inci-
dence of typhoid fever in 2000 followed by a sharp de-
cline in 2001 with incidence remaining below one case
per 100 K p-y from 2001 to 2011.
Aside from the rise in incidence in 1998 and 2000,
the incidence of typhoid fever in active duty military
personnel from 2001 to 2011 was consistent with
estimates of incidence in the U.S. during that time
period. Approximately 5700 cases of typhoid fever
(400 reported) occur annually in the U.S. with the ma-
jority of these cases related to travel to endemic areas
[1]. Though not directly able to analyze all travel of
our population, one hypothesis could be that increased
operational deployment of troops to communities en-
demic with S. Typhi could account for the rise in cases
in 1998 and 2011.
There were various deployments of U.S. military
personnel to countries with either medium incidence esti-
mates (ten cases per 100 K p-y) or high incidence esti-
mates (100 cases per 100 K p-y) of typhoid fever from
1998 to 2000 such as Kenya, Bosnia, Kosovo, Afghanistan,
and Iraq [3, 12]. However, these deployments were rela-
tively small averaging between 2000 and 8000 troops per
deployment compared to Operation Enduring Freedom
(2001–2014, Afghanistan) and Operation Iraqi Freedom
(2003–2010, Iraq), in which over 75,000 troops were de-
ployed in 2003 with the number of deployed personnel in-
creasing to over 180,000 in 2008 and tapering to 100,000
deployed personnel in 2011 [13]. Therefore, given the in-
crease in deployment of troops from 2003 onward, and
that travel to regions with higher incidence of typhoid
fever is a risk factor for contracting disease, one would an-
ticipate an increased incidence in S. Typhi amongst active
duty personnel during those years. One limitation of our
data is that deployment data were limited to operational
deployments and did not include non-operational deploy-
ments or non-deployment related travel. Illustrative of this
limitation is that we identified less than 10 S. Typhi cases
with a deployment temporally related to diagnosis. Add-
itionally, living conditions for deployed troops may not be
comparable to the native population who may lack proper
sanitation or access to clean food and water, as there are
many measures taken in order to maintain comfort of
troops to keep morale high. For example, as early as 2005
there was access to clean food and water in dining facil-
ities, air conditioning, libraries and other recreational fa-
cilities on U.S. military bases in Iraq [14]. Certainly, just as
travel to areas endemic of typhoid fever is a major risk fac-
tor for contracting the disease, we expect that operational
deployment to an area endemic of typhoid fever would
also increase the risk of disease [4, 5]. However, our data
insufficiently characterizes deployment-related exposures
as a risk factor for typhoid fever.
Vaccination against S. Typhi provides effective protec-
tion for individuals traveling to endemic regions and
may account in part for the low incidence of S. Typhi
cases seen in years of large operational deployments.
For example, in a retrospective study of S. Typhi inci-
dence in vaccinated vs unvaccinated travelers in Nepal,
88–100 % of travelers from North America, Western
Europe and Australia were vaccinated, and vaccines
Table 2 Typhoid cases demographics
Population S. Typhoid cases Active duty US
military populationa
<20 1 (0.5) 80,678 (5.7)
20–29 85 (41.5) 784,522 (55.5)
30–39 83 (40.5) 391,404 (27.7)
≥40 36 (17.6) 156,863 (11.1)
Race (n, %)
White 142 (69.3) 983,730 (69.6)
Black 20 (9.8) 234,750 (16.6)
Asian/Pacific Islander 18 (8.8) 66,742 (4.7)
American Indian 1 (0.5) 21,390 (1.5)
Other 19 (9.3) 121,418 (5.5)
Gender (n, %)
Male 176 (85.9) 1,205,034 (85.3)
Female 29 (14.2) 208,465 (14.7)
Education level (v, %)
High school 105 (51.2) 1,008,843 (71.4)
Some college 36 (17.6) 102,176 (7.2)
Bachelor’s degree 42 (20.5) 169,579 (12.0)
Master’s degree 14 (6.8) 83, 258 (5.9)
Doctorate 2 (1.0) 21,842 (1.6)
Unknown 6 (2.9) 27,801 (2.0)
Rank (n, %)
E1-E4 63 (30.7) 611,370 (43.3)
E5-E9 88 (42.9) 557,516 (39.4)
O1-O5 48 (23.4) 210,124 (14.9)
O6-O10 4 (2.0) 13,433 (1.0)
Warrant officer 2 (1.0) 21,029 (1.5)
Marital status (n, %)
Married 129 (62.9) 791,895 (56.0)
Never married/single 67 (32.7) 620,677 (43.9)
Other 9 (4.4) 927 (0.1)
Branch of service (n, %)
Army 38 (18.5) 533,249 (37.7)
Air force 73 (35.6) 330,214 (23.4)
Marines 14 (6.8) 194,432 (13.8)
Navy 78 (38.1) 314,580 (22.3)
Coast guard 2 (1.0) 41,024 (2.9)
aAs of April 2013
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Fig. 1 a. S. Typhi incidence by gender .
b. S. Typhi incidence by service .
c. S. Typhi incidence by race .
d. S. Typhi incidence by age
Table 3 Number (%) of typhoid fever cases with documented S. Typhi vaccination
Months pre-outcome Parenteral, other than
acetone-killed, dried
Vi capsule Parenteral acetone-killed
dried
Live oral Unspecified formulation Any
6 11 (5.4) 17 (8.3) 1 (0.5) 0 (0.0) 0 (0.0) 27 (13.2)
12 16 (7.8) 20 (9.8) 3 (1.5) 0 (0.0) 0 (0.0) 37 (18.1)
18 17 (8.3) 23 (11.3) 4 (2.0) 1 (0.5) 0 (0.0) 43 (21.1)
24 21 (10.3) 25 (12.3) 5 (2.5) 4 (2.0) 0 (0.0) 53 (26.0)
36 32 (15.7) 31 (15.2) 10 (4.9) 5 (2.5) 4 (2.0) 75 (36.8)
48 44 (21.6) 33 (16.2) 15 (7.4) 9 (4.4) 5 (2.5) 94 (46.1)
Any time 72 (35.3) 39 (19.1) 27 (13.2) 18 (8.8) 8 (3.9) 122 (59.8)
Data obtained from CVX codes as follows:
041: typhoid vaccine, parenteral, other than acetone-killed, dried
101: typhoid Vi capsular polysaccharide vaccine
053: typhoid vaccine, parenteral, acetone-killed, dried (U.S. military)
025: typhoid vaccine, live, oral
091: typhoid vaccine, unspecified formulation
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were estimated to be 95 % effective [15]. In contrast, of
the 205 active duty servicemen found to have an S.
Typhi associated illness, only 26.0 % (n = 53) had a doc-
umented S. Typhi vaccination within 2 years of
diagnosis.
Interestingly, only 18.1 % (n = 37) of subjects received
a typhoid vaccine within 1 year of diagnosis of S. Typhi.
Though not able to directly estimate vaccine efficacy,
the low prevalence of Typhoid in recently vaccinated
subjects may reflect the relatively high efficacy of these
vaccines, or alternatively, the broad-based coverage of S.
typhi vaccines in this population.
The most commonly administered vaccine was “any
parenteral vaccine other than AKD”, which was adminis-
tered to 35.3 % (n = 72) of subjects. However, the data of
vaccines was categorical and linked to vaccination codes,
and therefore information is limited on what specific
vaccinations are included in the category “any parenteral
vaccine other than AKD.” This category may include
both the Vi polysacharride vaccine and the heat-phenol
(H-P) vaccine, or may just be the H-P vaccine alone.
Nevertheless, 3-year cumulative efficacy rates for the Vi
vaccine and the H-P vaccine are estimated to be 30–70 %
and 51–77 %, respectively [7, 10]. Although our data do
not necessarily demonstrate the protective effect of ty-
phoid vaccine, the current military policy of vaccinating
all active duty servicemen before deployment to areas
endemic of S. Typhi likely lowers the incidence of S. Typhi
amongst this population, given the high efficacy of existing
typhoid vaccines.
Clinically, patients infected with S. Typhi or S. Paratyphi
present with nearly identical symptoms and are catego-
rized as having typhoid or paratyphoid fever based on
diagnostic testing results [6, 16, 17]. Diagnosis can be
made by isolating the organism from blood, stool or bone
marrow or through serological testing, however these tests
vary in reliability and in the manner in which they are
gathered [2, 18]. When culturing for S.Typhi or S. Paraty-
phi, the sensitivity of blood culture ranges between 20 and
66 % and the sensitivity of bone marrow culture ranges
from 48 to 100 % [6, 18–20]. Additionally, logistical con-
straints limit the availability of culture capability in de-
ployed settings increasing the difficulty of S. Typhi
diagnosis [6]. New, rapid, kit-based serologic tests with
higher sensitivity may improve diagnostic capabilities in
specific scenarios [2]. Our cases were identified by ICD9-
CM code, which may or may not have included the afore-
mentioned confirmatory testing and does not include
information on location of diagnosis. Therefore, the sensi-
tivity and specificity of diagnostic testing used to confirm
S. Typhi infection may have varied from patient to patient
and it is possible that subjects identified as having S.
Typhi, may actually have been infected with S. Paratyphi
or have been false positives. Distinguishing S. Paratyphi
infection from S. Typhi may help to better characterize
the burden and aetiology of enteric fever amongst active
duty military personell [3, 21, 22].
Conclusion
Although limitations of this retrospective study include
the utilization of medical encounter data obtained from
ambulatory and inpatient claims data, limited informa-
tion about method of diagnosis, vaccine status, deploy-
ment locations, and possible selection bias, this series of
cases reveals important epidemiological information that
may help guide preventive care against S. Typhi infec-
tion amongst active duty servicemen. In order to best
guide preventive care, further research into deployment
history, vaccine utilization, and incidence of S. Paratyphi
infection should be explored.
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